Cook Biotech Inc.
Division of Cook Group Inc.
Latest From Cook Biotech Inc.
Recent advances in breast cancer surgical techniques, such as the advent of nipple-sparing mastectomy, along with growing physician acceptance of new biomaterials capable of improving outcomes following implant-based breast reconstruction, are making mastectomy and reconstruction surgery a more attractive treatment option for many breast cancer patients and will help drive strong growth in the US breast reconstruction market in the years ahead.
Hernia repair is a staple of the general surgeon’s practice, with more than two million procedures performed annually worldwide. However, the procedure has proven problematic due to the mesh products used to repair the hernia defect and their potential to cause complications over time. At the Fifth International Hernia Congress, held recently in New York City, physicians debated the pros and cons of the many hernia repair mesh products that are now available. Although the general consensus at the meeting was there is no “ideal mesh,” mesh manufacturers continue to innovate in this field, offering a host of new products for this $500+ million market, including a variety of biologic meshes for complex repairs, synthetic meshes with biologic-like properties, fully resorbable meshes, and meshes with bacteriostatic properties.
NIH-funded clinical trial publication rates sub-par, gaps in skin substitute products data, and more research news.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Cook Group Inc.
- Senior Management
- Umesh Patel, PhD, VP, General Mgr.
- Contact Info
Cook Biotech Inc.
Phone: (765) 497-3355
1425 Innovation Place
West Lafayette, IN 47906
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.